Background: For clinicians who work in respiratory medicine, the use of beta-blockers (BBs) has, for a long time, posed a dilemma because of the potential risk of bronchospasm and neutralization of the effectiveness of β-2 agonists.
Aims and Objectives: To observe the effect of nebivolol on clinical and spirometric parameters on patients with stable chronic obstructive pulmonary disease (COPD) and the effect of the reversibility magnitude on the nebivolol detrimental effects.
Materials and Methods: A total of 32 patients with age above 40 years regardless their smoking state from both genders were included in the study at College of Medicine, Babylon University from February 2014 to September 2016. The study was approved by Institutional Review Board. The study included the patients who were diagnosed as COPD. Patients were divided into two groups depending on the reversibility test in spirometric assessment.
Results: There were significant differences between means of forced expiratory flow (FEF), forced expiratory volume in 1 second (FEV1) and COPD assessment test (CAT) score before and after using of 3rd generation BB for all patients with COPD and patients with high reversibility percent while for patients with low reversibility percent were significant differences between means of FEF, while there were no significant differences between means of FEV1 and CAT score.
Conclusion: The reversibility percent can be used as an indicator for the adverse effect of BB on COPD patients.
Key words: Reversibility Test; Chronic Obstructive Pulmonary Disease; Nebivolol; Outcome Predictor
|
